RadNet operates in the healthcare diagnostics sector with 22% revenue growth and 57% analyst upside, but its quality score of 2.1 out of 10 reflects zero net margin, weak return on assets, no competitive moat, and mixed earnings execution — leaving this as a growth story that has not yet translated into business quality sufficient to meet minimum investment thresholds.
Thesis pillars
- Quality Below Minimum Floor→Stable
- Revenue Growth Momentum Recovery→Stable
- Mixed Earnings Execution→Stable
- +1 more pillar — see the Why tab for full reasoning
RadNet, Inc. (RDNT) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $68.00: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 13%; Below-average business quality.
RadNet operates 418 outpatient diagnostic imaging centers across nine US states, making it the largest operator by number of centers and revenue. Revenue comes from imaging services billed to a diverse payor mix including commercial insurers, Medicare/Medicaid, and capitation... Read more
Sell if holding. Engine safety override at $68.00: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 71. Score 5.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About RadNet, Inc.
About RadNet, Inc.
RadNet's 418 freestanding outpatient diagnostic imaging centers across nine states — Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, Texas, and Virginia — make it the largest such operator in the United States by both location count and annual imaging revenue. The Digital Health segment held 22 FDA clearances and 15 CE marks across its AI-enabled radiology software portfolio as of December 31, 2025, and the 2025 acquisition of ICAD Inc. added approximately 1,500 customers and breast cancer detection AI capabilities.
RadNet earns imaging service revenue from a diversified payor mix including commercial insurance companies, managed care capitation arrangements, and government programs such as Medicare and Medicaid. Capitation contracts accounted for approximately 6% of total net revenue in fiscal 2025, under which payors pay fixed per-patient-per-month fees and the company assumes utilization risk for the covered population. The Digital Health segment generates software revenue from over 2,000 global customers through enterprise radiology platforms including RIS/PACS systems, the DeepHealth OS operating system, and AI applications for mammography, lung, prostate, and ultrasound image interpretation. RadNet competes against independent imaging operators, private equity-backed chains, smaller regional operators, and hospital systems, differentiating through multi-modality centers that offer MRI, CT, PET, nuclear medicine, mammography, ultrasound, X-ray, and fluoroscopy at a single location.
Show full overview
RadNet's reimbursement structure subjects the company to ongoing CMS policy risk: on October 30, 2025, the Centers for Medicare & Medicaid Services released the calendar year 2026 Medicare Physician Fee Schedule final rule governing RadNet's payments. Medicare and Medicaid represent significant payor sources, and the 10-K notes that budget deficits during high-unemployment periods could reduce federal and state spending on healthcare programs. California-specific minimum wage increases enacted in 2024 raised compensation costs starting in 2025 for a state hosting more than 100 of RadNet's centers, while multi-year contracted reimbursement rates may not fully offset those labor cost increases.
See also: Healthcare · Diagnostics & Research
From RadNet, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-06Recent Developments — RadNet, Inc.
Latest news
- NEWS Radnet's DeepHealth Unit Receives FDA 510(k) Clearances For Two New Breast Suite Functionalities — benzinga Jun 25, 2026 positive
- NEWS Radnet Unit DeepHealth Launches Reporting Pro, An AI-Powered Tool For Generating Clinical Reports — benzinga Jun 10, 2026 positive
- NEWS RadNet Seeks $200 Million Incremental Term Loan To Fund Acquisitions, Expansion, And Strategic Growth Initiatives — benzinga Jun 3, 2026 positive
- NEWS Barclays Maintains Overweight on RadNet, Lowers Price Target to $65 — benzinga May 20, 2026 positive
- NEWS RadNet Raises FY2026 Sales Guidance from $2.460B-$2.520B to $2.490B-$2.550B vs $2.456B Est — benzinga May 11, 2026 positive
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -0.7%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $68.00: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $63.94. Score 5.2/10, moderate confidence.
Take-profit target: $78.08 (+13.6% upside). Prior stop was $63.94. Stop-loss: $63.94.
Quality below floor (2.1 < 4.0); Value-trap signals (2/5): Revenue declining (-11.6% YoY), Margin compression (op margin 1.5%).
RadNet, Inc. trades at a P/E of N/A (forward 72.9). TrendMatrix value score: 5.2/10. Verdict: Sell.
14 analysts cover RDNT with a consensus score of 4.3/5. Average price target: $90.
What does RadNet, Inc. do?RadNet operates 418 outpatient diagnostic imaging centers across nine US states, making it the largest operator by...
RadNet operates 418 outpatient diagnostic imaging centers across nine US states, making it the largest operator by number of centers and revenue. Revenue comes from imaging services billed to a diverse payor mix including commercial insurers, Medicare/Medicaid, and capitation arrangements (~6% of net revenue in 2025). A Digital Health segment develops and sells AI-enabled radiology software and RIS/PACS systems to 2,000+ customers globally.